Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.

ABSTRACT:

Background

statin treatment has increased also among people aged 80 years and over, but adverse effects potentially promoting frailty and loss of resilience are frequent concerns.

Methods

in the Helsinki Businessmen Study, men born in 1919-34 (original n = 3,490) have been followed up since the 1960s. In 2011, a random subcohort of home-living survivors (n = 525) was assessed using questionnaires and clinical (including identification of phenotypic frailty) and laboratory examinations. A 7-year mortality follow-up ensued.

Results

we compared 259 current statin users (median age 82 years, interquartile range 80-85 years) with 266 non-users (83; 80-86 years). Statin users had significantly more multimorbidity than non-users (prevalencies 72.1% and 50.4%, respectively, P

SUBMITTER: Luotola K 

PROVIDER: S-EPMC7306181 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature